Search PubMed⌕ Search

Biomedical subjects

B Ryffel

Publications and source records attributed to B Ryffel.

At least 163 records · Page 9Linked to original sources

Osteomas in OF-1 mice: no alteration in biologic behavior during long-term treatment with cyclosporine.

During the course of a long-term oral study in OF-1 mice for the assessment of any carcinogenic potential of the immunosuppressive agent cyclosporine (CS-A), a high incidence of osteomas was found in all treatment groups as well as in controls. The incidences of osteoma-bearing mice were 20% in control male and 30% in control female mice; the respective incidences in all treated mice were 14.7% for males and 38% for females. The osteomas were found to occur in multiple sites in 70% of control males, in 73.3% of control females, and from all treated groups in 54.5% of males and 64.9% of females. The pelvis and sacrum were most frequently involved (42%), followed by the hindlimbs (32%), the skull (14.5%), the vertebral column (6.5%), the forelimbs (4%), and the sternum and ribs (1%) in control animals. The distribution of osteomas was similar in treated mice and did not differ significantly from controls. Histologic and ultrastructural analysis confirmed benign osteomas with abundant C-type viral particles. Thus a previously unobserved spontaneous high incidence of osteomas was reported in OF-1 mice. Immunosuppressive treatment with CS-A did not change the incidence or the biologic behavior of these osteomas.

Animals↗

Comparison of the pharmacological profiles of cyclosporine, (Nva2)-cyclosporine and (Val2)dihydro-cyclosporine.

The pharmacological profiles of two new derivatives of the immunosuppressive drug, cyclosporine, is presented here. (Nva2)-CS has very similar properties to CS, but lacks the nephrotoxic side-effects. This derivative appears to be a potential successor to cyclosporine. (Val2)DH-CS seems to have a different spectrum of activities. It does not suppress humoral immunity and allograft rejection, but suppresses some types of cell-mediated immune responses. This derivative may prove useful in autoimmune situations where T cells are involved in the disease process.

Animals↗

Quantitative fluorescence analysis of cyclosporine binding to human leukocytes.

The purpose of this investigation was to estimate the binding of cyclosporine at the single-cell level on human peripheral lymphocytes, and to test possible identity of the cyclosporine-binding site with a common receptor of T cell activation. A dansyl-coupled derivative (Dans cyclosporine) was used as a fluorescent probe. The histograms of unseparated, labeled peripheral leukocytes obtained by a fluorescence-activated cell sorter (FACS) showed that Dans cyclosporine stained all leukocytes--but two distinct populations could be separated based on the intensity of fluorescence. The more brightly labeled cells consisted mainly of granulocytes and monocytes, whereas the less-bright cells represented the lymphocyte compartment. Fluorescence microscopy revealed binding on the membrane for both cell populations; the label was, however, rapidly internalized in phagocytes. For both populations binding was saturable, time and temperature dependent, and reversible. Half-saturation occurred at approximately 5 X 10(-7) M (Kd). With respect to lymphocyte subpopulations, no difference of cellular fluorescence was found between unseparated lymphocytes and T cell subsets. In addition, mitogens such as concanavalin A, phytohemagglutinin, phorbol 12-myristate 13-acetate, or OKT3 antibody did not inhibit Dans cyclosporine binding. These results clearly indicate that cyclosporine binds to all peripheral blood lymphocytes, and no preferential binding on T cell subsets can be detected.

Adult↗

Toxicological evaluation of cyclosporin A.

Toxicological studies in a variety of different animal species have shown that cyclosporin A (CS-A) is a unique immunosuppressant, since it does not cause myelotoxic, teratogenic, mutagenic, or carcinogenic effects. This is undoubtedly due to the fact CS-A produces its immunosuppressive effects by a specific action on T lymphocytes rather than by a cytotoxic mechanism. The incidence of acute inflammatory lesions was also not significantly higher in treated animals than in controls. Clear-cut organ toxicity only occurred in rats and cynomolgus monkeys, where at high doses nephro- and hepatotoxicity were observed.

Animals↗

Immunosuppressive effect of cyclosporin A in two lymphocyte transfer models in rats: comparison of in vivo and in vitro treatment.

The immunosuppressive effect of CS-A was first studied in the assay for local GvHR. 3 X 10(6) viable spleen cells from LEW rats were injected into one foot pad of LEW X BN hybrids and both PLN were weighed 7 days later. Treatment of the recipients with 3 doses of 50 mg/kg/day of CS-A suppressed this local GvHR. The effect was more pronounced when treatment started at the time of cell transfer rather than a few days before peak response. In vitro incubation of the cellular inoculum with CS-A also prevented local GvHR. Histology of the PLN confirmed the quantitative results expressed by the PLN index. CS-A was further investigated in the EAE model in LEW rats. It protected rats sensitised with spinal cord emulsified in complete Freund's adjuvant for as long as they were treated with CS-A. Treatment delayed until after the appearance of EAE also markedly improved their condition. Oral treatment of recipients with 50 mg/kg/day CS-A prevented the development of adoptive EAE following the transfer of lymphoid cells conditioned in vitro. The presence of 0.1-1.0 microgram CS-A in the medium of the sensitised lymphoid cells also inhibited the adoptive transfer of EAE. Finally, if the cells for the adoptive transfer were derived from CS-A-treated sensitised donors, they failed to induce EAE. Histological examination supported the symptomatic findings.

Animals↗

Differentiation of human T-lymphoid leukemia cells into cells that have a suppressor phenotype is induced by phorbol 12-myristate 13-acetate.

Treatment of cultured human T-lymphoid (CEM) leukemia cells with nanomolar concentrations of phorbol 12-myristate 13-acetate (PMA) resulted in a reduction in cell growth and in the acquisition of a surface antigenic pattern that is common to both suppressor and cytotoxic T lymphocytes. This antigenic pattern was detected by OKT monoclonal antibodies. PMA treatment did not cause the expression of a cytotoxic function but rather induced the expression of a suppressor cell marker. This marker was characterized by the ability of the treated CEM cells to suppress [3H]thymidine incorporation into phytohemagglutinin-activated peripheral blood lymphocytes. After 4 days of treatment of CEM cells from either cloned or the parental cell population with 16 nM PMA, 71-98% of the cells expressed reactivity with OKT3 and OKT8 antibodies whereas reactivity with OKT4 and OKT6 was detected in less than or equal to 1-8% of the cells. The CEM cells can be divided into five groups based on the antigenic patterns of cells from randomly isolated clones. The cells from four of these groups were characterized by either low or high reactivity with each of the four OKT antibodies. The antigenic pattern of the fifth group resembled that of the parent CEM cells. The acquisition of reactivity with the OKT3 antibody in the CEM cells after PMA treatment was dependent on both time and dose and did not require cell replication. Acquisition of reactivity with OKT3 antibody also occurred after treatment with phorbol 12,13-dibutyrate but not after treatment with phorbol 13-monoacetate, phorbol 12,13-diacetate, or dimethyl sulfoxide. These results indicate that treatment of CEM cells with PMA and related agents can cause the cells to express a phenotype that resembles that of a mature suppressor T lymphocyte.

Antibodies, Monoclonal↗

Cyclosporin receptors on human lymphocytes.

Utilizing (3H) cyclosporin C (3H CS-C), a dihydroderivative of cyclosporin A (CS-A), an assay for cyclosporin receptors on human peripheral blood lymphocytes was developed. The specific binding of (3H) CS-C was saturable, time-dependent, and reversible. A Kd of 1.2 x 10(-7) M and a maximum binding capacity (Bmax) of 7 pmol/10(6) cells was calculated from equilibrium binding studies. A Scatchard analysis confirmed a single population of high affinity binding sites and about 7 x 10(5) sites/cell. Kinetic analysis of specific binding at 37 degrees C yielded a pseudo-first order rate association constant of 1.1 x 10(6) M-1 min-1 and a zero order dissociation rate constant of 0.19 min-1. The Kd 1.7 x 10(-7) M calculated from kinetic studies agreed well with the value of 1.2 x 10(-7) M determined in equilibrium binding studies. Regarding the specificity of binding, (3H) CS-C binding to lymphocytes was inhibited with CS-A and CS-C; however, no inhibition with the biologically inert keto-CS-A was observed. Mitogens and various growth factors did not compete for the binding site when added simultaneously with the radiolabel. However, pretreatment with T cell mitogens such as PHA, Con A, or the OKT3 antibody reduced (3H) CS-C binding significantly. These results suggest that the binding site for CS-A is closely associated with the mitogenic receptor on lymphocytes.

Antibodies, Monoclonal↗

Cyclosporin A: effects on the mouse thymus.

Cyclosporin A (CY-A), an immunosuppressive cyclic endecapeptide, causes thymus weight reduction in mice 4 days after single oral administration. This effect was compared with that of hydrocortisone acetate (HCA), or of azathioprine (AZ). The latter had no effect on thymus weight, whereas HCA induced a marked reduction 2 days after administration. A possible mediation by the pituitary adrenal gland system (PAG) of the CY-A induced effect was suggested by the observation of an elevated corticosterone plasma level after CY-A administration and by the prevention of the thymocytolytic effect by adrenalectomy. However, the immunosuppressive activity of CY-A in humoral immunity and cell mediated tests was not affected by adrenalectomy. It must therefore be concluded that the immunosuppression produced by CY-A in vivo is not mediated by stimulation of the PAG system, contrary to its effect on the mouse thymus, which is a glucocorticosteroid effect.

Adrenalectomy↗

Cyclosporin receptor on mouse lymphocytes.

Specific binding of [3H]-cyclosporin C (3H-CS-C), an immunosuppressive oligopeptide, was characterized on different mouse lymphocytes. The binding was saturable, time-dependent and reversible; and KD of 1.5 x 10(-7) M and maximum binding capacity Bmax of 35 pmol/4 x 10(6) cells was found for thymocytes. A computerized analysis of the data confirmed a single population of high affinity binding sites. Lymphocytes of different organs differed in their Bmax: thymus greater than spleen greater than mesenteric lymph node (pure T cells) greater than mesenteric lymph node (pure B cells). Erythrocytes did not show a specific binding.

Animals↗

Increased lymphocyte load of postcapillary venules in regional lymph nodes following stimulation with antigen -- isologous antibody complexes as compared with antigen alone.

In an attempt to study changing patterns of lymphocyte influx from blood into lymph nodes following regional antigenic stimulation, mice were injected with either fluid tetanus toxoid alone or complexed (at equivalence) with isologous antibody. The mean number of lymphocytes inside the basement membrane of cross-sectioned postcapillary venules (PCV) was evaluated as a function of time after antigen injection. 'Lymphocyte load' of PCV (LL/PCV) began to increase within less than a day after antigenic stimulation. The initial increment of LL/PCV values in both primary and secondary responses was greater when complexed rather than fluid antigen was used. Peak values were reached earlier, i.e., at the end of day 2, in presensitized as compared with unprimed animals (day 4). Maximum values of mean LL/PCV did not reflect the magnitude of subsequent antibody production under all experimental conditions. We conclude that changes in the LL/PCV belong to early lymph node reactions following regional antigenic stimulation. The pattern of this particular response may vary according to the type of immunizing agent used and the state of immunity (sensitization) of the animal as well as other factors still to be elucidated.

Animals↗

Preclinical safety studies with recombinant human interleukin 6 (rhIL-6) in the primate Callithrix jacchus (marmoset): comparison with studies in rats.

The haemopoietic and immunostimulatory properties of recombinant human interleukin 6 (rhIL-6) might be used clinically in cancer patients. For the preclinical assessment of the safety of such a therapy, we chose the primate marmoset (Callithrix jacchus) and Wistar rats. Recombinant hIL-6 given to marmosets at doses of up to 1000 micrograms kg-1 day-1 over 4 and 9 weeks did not induce fever and was very well tolerated. Haematological alterations included a sustained two- to threefold increase of thrombocyte counts, peaking at 4 weeks, as well as an increase in neutrophils and basophils. The number of bone marrow megakaryocytes at 4 and 9 weeks was not increased, but the ploidy grade was augmented. An acute-phase protein response was observed within 24 h after the first IL-6 administration, which reached a maximum after 1 week. The acute-phase protein response was not accompanied by functional or morphological signs of hepatocellular damage. Increased immunoglobulin and soluble IL-2 receptor in the serum levels reflected systemic immunostimulation. Recombinant hIL-6 was also given to rats at 500 micrograms kg-1 day-1 s.c. for 4 weeks, where it induced a stimulation of thrombopoiesis associated with increased platelet counts within 1 week. Furthermore, rhIL-6-treated rats had signs of immunostimulation and increased acute-phase reactants in serum, as in marmosets. There was no evidence of renal glomerular or hepatic pathology.(ABSTRACT TRUNCATED AT 250 WORDS)

Acute-Phase Proteins↗

Effects of immunopharmacological compounds in the Lyme arthritis model using normal and SCID mice.

The murine Lyme borreliosis causes a special type of arthritis whose development appears to be controlled by a functioning immune system. Immunocompetent C3H and severe combined immunodeficient (SCID) mice were infected with Borrelia burgdorferi (strain SH-2-82) to induce experimental Lyme disease. Expression of clinical symptoms was mild to very moderate in the C3H but more rapidly developing and severe in the SCID mouse. Various pharmacological compounds, such as anti-inflammatory and immunosuppressive drugs, monoclonal antibodies and other miscellaneous agents, were investigated for profiling their effects in this model in both mouse strains. Several disease parameters were assessed, in particular paw swelling. The use of these various compounds provided further evidence that experimental borreliosis in mice represents a special type of arthritis which has no autoimmune basis and which requires productive infection with Borrelia burgdorferi. In addition, when comparing these results with those obtained in other mainly immune driven arthritis models commonly used in inflammation research, it is concluded that this arthritis model is not suitable for the therapeutic assessment of antiinflammatory agents.

Adjuvants, Immunologic↗

Tumor necrosis factor receptor 2 plays a minor role for mycobacterial immunity.

Tumor necrosis factor (TNF) signalling via the TNF receptor 1 (TNF-R1) is required for host resistance to mycobacterial infection. The role of TNF-R2 in anti-mycobacterial immunity is not known. Therefore, we compared TNF-R1 and TNF-R2 knockout (KO) mice infected with Mycobacterium bovis BCG (10(7) CFU, i.v.). While the bacterial burden of TNF-R1-deficient mice was significantly increased and the mice succumbed to infection between 4 and 5 weeks, TNF-R2 KO mice were less sensitive, and only 3 of 10 mice died within 12 weeks. Wild-type (WT) mice were resistant to BCG infection. The inability to clear the infection of TNF-R1 KO mice was associated with a reduced delayed-type hypersensitivity (DTH) response to purified protein derivative and severe impairment in forming granulomas with reduced macrophage recruitment and activation, and diminished expression of adhesion molecules. By contrast, TNF-R2 KO mice developed normal DTH response and mature mycobactericidal granulomas as the WT mice. Therefore, anti-mycobacterial immunity is largely dependent on TNF signalling via the TNF-R1, while activation of TNF-R2 plays a minor role.

Animals↗

Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase.

Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days. The molecular mechanisms of CsA and FK506 toxicity were investigated. Cyclophilin A and FK506-binding protein, the main intracytoplasmic receptors for CsA and FK506, respectively, were each detected in renal tissue extract. In the kidney, high levels of immunoreactive and enzymatically active calcineurin were found which were inhibited by the immunosuppressants CsA and FK506, but not by rapamycin. Finally, specific immunophilin-drug-calcineurin complexes formed only in the presence of CsA and FK506, but not rapamycin. These results suggest that the nephrotoxic effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase.

Animals↗

Characterization of interleukin-13 receptor in carcinoma cell lines and human blood cells and comparison with the interleukin-4 receptor.

The interleukin-13 receptor is characterized by ligand-binding and crosslinking studies and compared with the interleukin-4 receptor. Crosslinking of radio-labeled hIL-4 and hIL-13 to the receptors on human carcinoma and mast cell lines demonstrated a predominant subunit at 130 kDa with two other minor bands of lower molecular mass (75 kDa and 65 kDa) in autoradiography. All binding of 125I-IL-13 was specifically blocked when the carcinoma cell suspensions were incubated with an excess of unlabeled hIL-4. However, unlabeled hIL-13 was unable to completely displace 125I-hIL-4 from the 130 kDa protein. In addition, 125I-hIL-13 showed no binding to mouse fibroblast cells transfected with human 130 kDa hIL-4 receptor c-DNA. Using weighted nonlinear computer modeling of the data from several equilibrium binding studies with human mast cells, a model of two binding sites for IL-4 (Kd = 50 and 190 pmol/L) and one site for IL-13 (Kd = 100 pmol/L) fitted better than a one site model with a very high level of significance (F = 10.66, P < 0.0001). It can be concluded that human IL-4R and hIL-13R are similar but distinct. This conclusion is supported here for the first time by a strong statistical criterion.

Antigens, CD↗